Influence of vitreomacular interface score on treatment outcomes of anti-VEGF therapy for neovascular age-related macular degeneration
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2056-9920
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Influence of vitreomacular interface score on treatment outcomes of anti-VEGF therapy for neovascular age-related macular degeneration ; volume:7 ; number:1 ; day:20 ; month:12 ; year:2021 ; pages:1-8 ; date:12.2021
International Journal of Retina and Vitreous ; 7, Heft 1 (20.12.2021), 1-8, 12.2021
- Urheber
-
Miyata, Manabu
Ooto, Sotaro
Yamashiro, Kenji
Tamura, Hiroshi
Uji, Akihito
Miyake, Masahiro
Muraoka, Yuki
Takahashi, Ayako
Tsujikawa, Akitaka
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40942-021-00342-4
- URN
-
urn:nbn:de:101:1-2022041421082078461953
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Miyata, Manabu
- Ooto, Sotaro
- Yamashiro, Kenji
- Tamura, Hiroshi
- Uji, Akihito
- Miyake, Masahiro
- Muraoka, Yuki
- Takahashi, Ayako
- Tsujikawa, Akitaka
- SpringerLink (Online service)
Ähnliche Objekte (12)
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Hyperreflective material evolution patterns during long term anti-VEGF therapy in neovascular age-related macular degeneration
Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
Reasons for Delayed Anti-VEGF Treatment During COVID-19 Lockdown and Clinical Impact in Neovascular Age-Related Macular Degeneration
Fluid dynamics between injections in incomplete anti-VEGF responders within neovascular age-related macular degeneration: a prospective observational study
Atrophy of retinal vessels in neovascular age-related macular degeneration following long-term treatment with 20 intravitreal anti-VEGF injections
A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
Prediction of the short-term efficacy of anti-VEGF therapy for neovascular age-related macular degeneration using optical coherence tomography angiography
Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Hyperreflective material evolution patterns during long term anti-VEGF therapy in neovascular age-related macular degeneration
Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
Reasons for Delayed Anti-VEGF Treatment During COVID-19 Lockdown and Clinical Impact in Neovascular Age-Related Macular Degeneration
Fluid dynamics between injections in incomplete anti-VEGF responders within neovascular age-related macular degeneration: a prospective observational study
Atrophy of retinal vessels in neovascular age-related macular degeneration following long-term treatment with 20 intravitreal anti-VEGF injections
A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
Prediction of the short-term efficacy of anti-VEGF therapy for neovascular age-related macular degeneration using optical coherence tomography angiography
Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Hyperreflective material evolution patterns during long term anti-VEGF therapy in neovascular age-related macular degeneration
Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
Reasons for Delayed Anti-VEGF Treatment During COVID-19 Lockdown and Clinical Impact in Neovascular Age-Related Macular Degeneration
Fluid dynamics between injections in incomplete anti-VEGF responders within neovascular age-related macular degeneration: a prospective observational study
Atrophy of retinal vessels in neovascular age-related macular degeneration following long-term treatment with 20 intravitreal anti-VEGF injections
A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
Prediction of the short-term efficacy of anti-VEGF therapy for neovascular age-related macular degeneration using optical coherence tomography angiography
Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study